KARD

EX-99.1

2 ck0002123613-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

PRESS RELEASE

Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates

Continued to advance the development of three late-stage programs, supported by the Prolaio platform, aimed at addressing cardiovascular diseases where no approved treatments exist

Danicamtiv KINSHIP-DCM Phase 3 Cohort 1 enrollment now underway; Phase 2b topline data expected 1H 2027

Strong cash position of $661 million following recent IPO extends runway through multiple data readouts and initiation of Phase 3 clinical trials

SOUTH SAN FRANCISCO, CA, and PRINCETON, NJ, AUG 11, 2026 — Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan” or “the Company”), a clinical-stage precision therapeutics company developing medicines that target the root causes of cardiovascular diseases with no approved treatments, today reported financial results from the second quarter ended June 30, 2026, and provided recent business updates.

“Our IPO has positioned Kardigan to advance a portfolio of late-stage cardiovascular programs to address diseases where patients urgently need better treatment options,” said Tassos Gianakakos, co-founder, chief executive officer, and chair of the board of Kardigan. “As we initiate our Phase 3 KINSHIP-DCM trial, dose patients in our Phase 2b KARDINAL-ASH trial, and continue enrollment in our Phase 2b KATALYST-AV trial, we are entering a pivotal period with multiple clinical milestones expected over the next 12 months that will shape the registrational path for each of our medicines.”

Second Quarter 2026 and Recent Business Highlights

Danicamtiv: myosin activator in development for genetic DCM

• Danicamtiv is designed to restore myosin function and availability, directly targeting the underlying sarcomeric defects in genetic dilated cardiomyopathy (DCM).

• Danicamtiv is currently being evaluated in the Company’s KINSHIP-DCM Phase 2b/3 adaptive, randomized, placebo-controlled clinical trial.

• Preclinical and clinical evidence linking danicamtiv treatment to improvements in right ventricular function to be presented at the upcoming European Society of Cardiology Congress (ESC 2026). [Session: Late-Breaking Basic and Translational Science; Sunday, Aug 30th at 8:15 AM CEST]

• In July, the Company completed enrollment of Cohort 1 (myosin heavy chain 7, or MYH7, and titin, or TTN, patients) of the Phase 2b KINSHIP-DCM clinical trial and enrollment of the Phase 3 portion is now underway. The Company expects to share Phase 2b topline data in the first half of 2027.

Ataciguat: soluble guanylate cyclase (sGC) activator in development for CAVS

• Ataciguat targets valvular interstitial cells to slow osteogenic and calcific remodeling, an underlying driver of disease progression in calcific aortic valve stenosis (CAVS), and has demonstrated direct myocardial effects in improving both systolic and diastolic function, a hallmark of progressive disease that results in valvular heart failure.

• Ataciguat is currently being evaluated in the Company’s KATALYST-AV Phase 2b clinical trial in CAVS patients with moderate disease. The Company expects to share Phase 2b topline data from the interim 24-week analysis in the first half of 2027.

Tonlamarsen: antisense oligonucleotide in development for ASH

• Tonlamarsen targets hepatic angiotensinogen (AGT) for the management of blood pressure in acute severe hypertension (ASH) post-hospitalization.

• Extended follow-up data from an earlier KARDINAL clinical trial assessing the effect of Tonlamarsen in uncontrolled hypertension will be presented at the upcoming European Society of Cardiology Congress (ESC 2026). [Session: Late-Breaking Clinical Science: renin-angiotensin-aldosterone pathway inhibition; Sunday, Aug 30th from 1:45 - 3:00 PM CEST]

• Tonlamarsen is currently being evaluated in the Company’s KARDINAL-ASH Phase 2 clinical trial. In the second quarter, the Company randomized the first patient in KARDINAL-ASH and expects to share Phase 2 topline data in the first half of 2027.

Additional Highlights

• In June, the Company announced the closing of its initial public offering with aggregate gross proceeds of $460 million (before deducting underwriting discounts, commissions, and other offering expenses). Current cash runway supports continued advancement of danicamtiv, ataciguat, and tonlamarsen through clinical data readouts and the initiation of Phase 3 clinical trials across all three programs.

Second Quarter Financial Results

• Cash Position: Cash, cash equivalents and investments were $660.7 million as of June 30, 2026, compared to $335.5 million as of December 31, 2025. The increase reflects net proceeds from the Company’s initial public offering in June 2026, offset by cash used in operations.

• R&D Expenses: Research and development expenses were $56.4 million for the quarter ended June 30, 2026, compared to $35.8 million for the comparable prior-year period. The increase was primari